Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 in Small Cell Lung Cancer
NCT06592638Phase 1Recruiting
- Sponsor
- Zelgen
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alveltamig in small cell lung cancer (SCLC), sponsored by Zelgen. Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 2 years and 4 more. Started Mar 2025; status: recruiting.
02
Drugs
alveltamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06592638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592638.